The Use of Statins for Myocardial Death Prevention

Rambam Health Care Campus25 enrolled

Overview

The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Myocardial Infarction

Interventions

AtorvastatinDRUG

Oral Atorvastatin

Eligibility

Sex: ALLMin age: 30 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1\. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study. Exclusion Criteria: 1. The impossibility to give the required informed consent. 2. Known allergy to Atorvastatin. 3. Base line serum creatinine of 1.4 mg/dL. 4. Killip Classification 3 and 4. 5. Persisting vomiting. 6. History of previous liver disease. 7. History of previous muscle disease or rabdomyolisis. 8. Treated already with high dose atorvastatin 9. Non Compliance.

Locations (1)

Rambam Health Care Campus

Haifa, Haifa District, Israel

Outcomes

Primary Outcomes

Heart EcoCardiography and specific laboratory tests

Time frame: Base line, second day and 60 days after myocardial infarction

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.